Jean Francois Dufour

Summary

Affiliation: University of Bern
Country: Switzerland

Publications

  1. doi request reprint Intermediate hepatocellular carcinoma: current treatments and future perspectives
    J F Dufour
    Hepatology, Department of Clinical Research, University of Berne, Berne, Switzerland
    Ann Oncol 24:ii24-9. 2013
  2. ncbi request reprint Anti-angiogenic therapy for HCC
    J F Dufour
    Hepatology Department of Clinical Research, University of Bern, Bern, Switzerland
    Minerva Gastroenterol Dietol 58:81-6. 2012
  3. ncbi request reprint Expression of inositol 1,4,5-trisphosphate receptor isoforms in rat cirrhosis
    J F Dufour
    Department of Clinical Pharmacology, University of Bern, Switzerland
    Hepatology 30:1018-26. 1999
  4. ncbi request reprint Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis
    Jean Francois Dufour
    Institute of Clinical Pharmacology, University of Bern, Bern, and Department of Gastroenterology, University Hospital of Lausanne, Switzerland
    Clin Gastroenterol Hepatol 4:1537-43. 2006
  5. ncbi request reprint [Alcoholic and non-alcoholic steatohepatitis]
    J F Dufour
    Institut für klinische Pharmakologie der Universität Bern
    Ther Umsch 61:505-12. 2004
  6. ncbi request reprint Tumour suppressors in liver carcinogenesis
    Jean Francois Dufour
    Institute of Clinical Pharmacology, University of Berne, Berne, Switzerland
    J Hepatol 47:860-7. 2007
  7. ncbi request reprint What is the current treatment of PTLD after liver transplantation?
    Jean Francois Dufour
    Department of Clinical Pharmacology, University of Bern, Murtenstrasse 35, 3010 Bern, Switzerland
    J Hepatol 44:23-6. 2006
  8. ncbi request reprint Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare
    Jean Francois Dufour
    Department of Clinical Pharmacology, University of Berne, Murtenstrasse 35, 3010 Bern, Switzerland
    J Hepatol 37:748-52. 2002
  9. ncbi request reprint Survival pathways and preconditioning in liver transplantation
    Jean Francois Dufour
    Institute for Clinical Pharmacology, University of Bern, Switzerland
    Transpl Immunol 9:239-41. 2002
  10. ncbi request reprint [Phytotherapeutic drugs in gastroenterology and hepatology]
    J F Dufour
    Institut fur Klinische Pharmakologie, Universitat Bern
    Ther Umsch 59:313-6. 2002

Detail Information

Publications55

  1. doi request reprint Intermediate hepatocellular carcinoma: current treatments and future perspectives
    J F Dufour
    Hepatology, Department of Clinical Research, University of Berne, Berne, Switzerland
    Ann Oncol 24:ii24-9. 2013
    ..This narrative review will present and discuss the most recent evidence on the locoregional or medical treatment with sorafenib in patients with intermediate-stage HCC...
  2. ncbi request reprint Anti-angiogenic therapy for HCC
    J F Dufour
    Hepatology Department of Clinical Research, University of Bern, Bern, Switzerland
    Minerva Gastroenterol Dietol 58:81-6. 2012
    ..This manuscript reviews the rationale for targeting the vascular cells to treat hepatocellular carcinoma, the signalling pathways underlying angiogenesis and the most promising drugs...
  3. ncbi request reprint Expression of inositol 1,4,5-trisphosphate receptor isoforms in rat cirrhosis
    J F Dufour
    Department of Clinical Pharmacology, University of Bern, Switzerland
    Hepatology 30:1018-26. 1999
    ..Signaling through inositol trisphosphate receptor participates in the pathogenesis of cirrhosis, because this process affects the expression of its isoforms...
  4. ncbi request reprint Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis
    Jean Francois Dufour
    Institute of Clinical Pharmacology, University of Bern, Bern, and Department of Gastroenterology, University Hospital of Lausanne, Switzerland
    Clin Gastroenterol Hepatol 4:1537-43. 2006
    ..UDCA and vitamin E have been considered separately as therapeutic options and have not been shown to be effective. This study tested their combination...
  5. ncbi request reprint [Alcoholic and non-alcoholic steatohepatitis]
    J F Dufour
    Institut für klinische Pharmakologie der Universität Bern
    Ther Umsch 61:505-12. 2004
    ..Therefore, similar pathogenetic mechanisms are supposed. However, therapeutic approaches are different. Treatment of choice in ASH is alcohol abstinence, that of NASH the reduction of insulin resistance, primarily by weight loss...
  6. ncbi request reprint Tumour suppressors in liver carcinogenesis
    Jean Francois Dufour
    Institute of Clinical Pharmacology, University of Berne, Berne, Switzerland
    J Hepatol 47:860-7. 2007
    ....
  7. ncbi request reprint What is the current treatment of PTLD after liver transplantation?
    Jean Francois Dufour
    Department of Clinical Pharmacology, University of Bern, Murtenstrasse 35, 3010 Bern, Switzerland
    J Hepatol 44:23-6. 2006
  8. ncbi request reprint Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare
    Jean Francois Dufour
    Department of Clinical Pharmacology, University of Berne, Murtenstrasse 35, 3010 Bern, Switzerland
    J Hepatol 37:748-52. 2002
    ..Autoimmune hepatitis can present acutely and pursues a variable, usually progressive course. Spontaneous remissions have been described, but their influence on the course of subsequent attacks has not yet been studied...
  9. ncbi request reprint Survival pathways and preconditioning in liver transplantation
    Jean Francois Dufour
    Institute for Clinical Pharmacology, University of Bern, Switzerland
    Transpl Immunol 9:239-41. 2002
  10. ncbi request reprint [Phytotherapeutic drugs in gastroenterology and hepatology]
    J F Dufour
    Institut fur Klinische Pharmakologie, Universitat Bern
    Ther Umsch 59:313-6. 2002
    ..On the other hand phytotherapeutic preparations can not be recommended at present for the treatment of cirrhosis or chronic viral hepatitis based on the available data...
  11. doi request reprint Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma
    Anne Christine Piguet
    Hepatology, Department of Clinical Research, University of Berne, Berne, Switzerland
    Mol Cancer Ther 10:1007-17. 2011
    ..Everolimus retains antitumoral properties when administered sequentially after sorafenib. This supports the clinical use of everolimus in HCC, both in combination with sorafenib or after sorafenib...
  12. ncbi request reprint Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice
    Claudio A Redaelli
    Department of Visceral and Transplantation Surgery, Inselspital, University of Bern, Bern, Switzerland
    J Hepatol 40:305-12. 2004
    ..Vascular endothelial growth factor (VEGF) promotes angiogenesis. Hepatic steatosis delays regeneration and increases liver resection morbidity. We hypothesized that VEGF overexpression stimulates hepatic regeneration...
  13. pmc Preoperative galactose elimination capacity predicts complications and survival after hepatic resection
    Claudio A Redaelli
    Department of Visceral and Transplantation Surgery, University of Bern, Bern, Switzerland
    Ann Surg 235:77-85. 2002
    ..To analyze a single center's 6-year experience with 258 consecutive patients undergoing major hepatic resection for primary or secondary malignancy of the liver, and to examine the predictive value of preoperative liver function assessment...
  14. ncbi request reprint Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma
    David Semela
    Institute of Clinical Pharmacology, University of Berne, Murtenstrasse 35, CH 3010 Berne, Switzerland
    J Hepatol 46:840-8. 2007
    ..Their antiproliferative and antiangiogenic properties suggest that these drugs could be considered to treat HCC. We investigated the antitumoral effects of mTOR inhibition in a HCC model...
  15. doi request reprint Ablation of the tumor suppressor histidine triad nucleotide binding protein 1 is protective against hepatic ischemia/reperfusion injury
    Juliette Martin
    Institute of Clinical Pharmacology and Visceral Research, University of Bern, Bern, Switzerland
    Hepatology 53:243-52. 2011
    ..These effects increased survival after I/R in mice lacking Hint1. Hint1(-/-) Kupffer cells were less activated than control cells after stimulation with lipopolysaccharides...
  16. ncbi request reprint Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C
    Caroline Hora
    Department of Clinical Pharmacology, University of Bern, Bern, Switzerland
    Liver Int 28:370-6. 2008
    ..We hypothesized that CTGF may link steatosis, insulin resistance and fibrosis...
  17. ncbi request reprint Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition
    Lifu Wang
    Department of Clinical Pharmacology, University of Bern, Switzerland
    Hepatology 41:1241-51. 2005
    ..In conclusion, TUDCA activates CREB in cholangiocytes, reducing the apoptotic effect of CCI-779. These findings suggest a novel cytoprotective mechanism for this bile acid...
  18. pmc Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma
    Juliette Martin
    Institute for Clinical Pharmacology, University of Bern, Bern, Switzerland
    Gastroenterology 130:2179-88. 2006
    ..Hints, histidine triad nucleotide-binding proteins, are adenosine monophosphate-lysine hydrolases of uncertain biological function. Here we report the characterization of human Hint2...
  19. doi request reprint Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma
    Lorenz Kuske
    Hepatology, Department of Clinical Research, University of Berne, Switzerland
    Swiss Med Wkly 142:w13651. 2012
    ..This study analyses the characteristics of the patients with chronic hepatitis C participating in the Swiss Hepatitis C Cohort Study who developed HCC...
  20. pmc Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study
    Jean Francois Dufour
    University Clinic for Visceral Surgery and Medicine, University of Berne, CH 3010 Berne, Switzerland
    Oncologist 15:1198-204. 2010
    ..It is unknown whether sorafenib can be combined with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. This study assesses the safety and tolerability of a continuous regimen of sorafenib combined with TACE...
  21. ncbi request reprint Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis
    Haithem Chtioui
    Institute of Clinical Pharmacology, University of Bern, Bern, Switzerland
    Liver Int 27:764-71. 2007
    ..The pathogenesis of NASH implicates the overexpression of cytochrome P450 2E1 (CYP2E1). We investigated whether the noninvasive determination of CYP2E1 activity could replace a liver biopsy in order to differentiate NASH from NAFL...
  22. doi request reprint Disruption of the histidine triad nucleotide-binding hint2 gene in mice affects glycemic control and mitochondrial function
    Juliette Martin
    Division of Hepatology, Department of Clinical Research, University of Berne, Berne, Switzerland
    Hepatology 57:2037-48. 2013
    ..Conclusion: Hint2/HINT2 positively regulates mitochondrial lipid metabolism and respiration and glucose homeostasis. The absence of Hint2 provokes mitochondrial deformities and a change in the pattern of acetylation of selected proteins...
  23. doi request reprint Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma
    Caroline Erös de Bethlenfalva-Hora
    Hepatology, Department of Clinical Research, University of Bern, Bern, Switzerland
    Clin Sci (Lond) 126:243-52. 2014
    ..0001). RFA and sorafenib alone resulted in significant volume reduction of the non-RFA-targeted tumour; this effect was enhanced when both modalities were combined. ..
  24. ncbi request reprint Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2
    Patrik Roth
    Institute of Pathology, University of Bern, Bern, Switzerland
    J Drug Target 15:623-31. 2007
    ..053; 1 way ANOVA with 4 groups). These findings suggest that IL designed to bind specifically to VEGFR-2 can be used to deliver doxorubicin to the tumour endothelium and may impair the "angiogenic switch" of the tumours...
  25. doi request reprint Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN
    Anne Christine Piguet
    Institute of Clinical Pharmacology and Visceral Research, University of Bern, CH 3010 Bern, Switzerland
    Clin Sci (Lond) 118:401-10. 2010
    ....
  26. ncbi request reprint Ablation of the tumor suppressor histidine triad nucleotide binding protein 1 is protective against hepatic ischemia/reperfusion injury
    Juliette Martin
    Institute of Clinical Pharmacology and Visceral Research, University of Bern, Bern, Switzerland
    Hepatology 53:243-52. 2011
    ..Conclusion: The Hint1 protein influences the course of I/R injury, and its ablation in Kupffer cells may limit the extent of the injury. (HEPATOLOGY 2011)...
  27. doi request reprint Targeting vessels to treat hepatocellular carcinoma
    Pamela Romanque
    Institute of Clinical Pharmacology, University of Bern, CH 3010 Bern, Switzerland
    Clin Sci (Lond) 114:467-77. 2008
    ..The present review highlights the evidence for the role of angiogenesis in HCC (hepatocellular carcinoma) and discusses the increasing importance of inhibitors of angiogenesis in HCC therapy...
  28. ncbi request reprint Unusual evolution of posterior reversible encephalopathy syndrome (PRES) one year after liver transplantation
    Haithem Chtioui
    Department of Clinical Pharmacology, Inselspital, Bern, Switzerland
    Liver Transpl 11:588-90. 2005
  29. doi request reprint Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis
    Maria Luisa Balmer
    Institute of Clinical Pharmacology and Visceral Research, University of Berne, Berne, Switzerland
    Liver Int 29:1184-8. 2009
    ..In a randomized trial ursodeoxycholic acid (UDCA) with vitamin E (VitE) improved serum aminotransferases and hepatic histology. The present work evaluates the effect of this combination on adipokines and hepatocellular apoptosis...
  30. pmc Significance of serum adiponectin levels in patients with chronic liver disease
    Maria Luisa Balmer
    Institute of Clinical Pharmacology and Visceral Research, University of Bern, Bern, Switzerland
    Clin Sci (Lond) 119:431-6. 2010
    ..In conclusion, adiponectin levels correlate positively with surrogate markers of hepatic fibrosis (transient elastography, fasting serum bile acids and hyaluronate) and are significantly elevated in cases of cirrhosis...
  31. ncbi request reprint Angiogenesis and hepatocellular carcinoma
    David Semela
    Institute of Clinical Pharmacology, University of Bern, 35 Murtenstrasse, Bern CH 3010, Switzerland
    J Hepatol 41:864-80. 2004
  32. ncbi request reprint Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases
    Yogesh Vashist
    Department of Clinical Pharmacology, University of Bern, Murtenstrasse 35, Bern 3010, Switzerland
    Med Hypotheses 62:82-5. 2004
    ..Pharmacological intervention at this level might be beneficial to treat complications like ascites and variceal bleeding...
  33. ncbi request reprint Biomarkers for hepatocellular apoptosis in the management of liver diseases
    Marie V St-Pierre
    Institute of Clinical Pharmacology and Visceral Research, University of Bern, Murtenstrasse 35, Bern, Switzerland
    Curr Pharm Biotechnol 13:2221-7. 2012
    ..The potential for non-invasive biomarkers of apoptosis to gauge the extent and follow the evolution of clinical disease is emphasized...
  34. ncbi request reprint Liver surgery in the era of tissue-preserving resections: early and late outcome in patients with primary and secondary hepatic tumors
    Claudio A Redaelli
    Department of Visceral and Transplantation Surgery, University of Bern, Inselspital, CH 3010 Bern, Switzerland
    World J Surg 26:1126-32. 2002
    ..Therefore, tissue-preserving resection is especially useful for patients with hepatocellular carcinomas and cirrhosis...
  35. ncbi request reprint Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver
    Jan Plock
    Clinic of Visceral and Transplantation Surgery, Department of Clinical Research, University of Bern, Murtenstrase 35, 3010 Bern, Switzerland
    J Hepatol 47:538-45. 2007
    ..We investigated the molecular response of a non-ischemic hypoxic stress in the liver, in particular, to distinguish its hepatoprotective potential...
  36. doi request reprint [Non-alcoholic steatohepatitis - from NAFLD to MAFLD]
    Maria Luisa Balmer
    Universitätsklinik für Viszerale Chirurgie und Medizin, Bern
    Ther Umsch 68:183-8. 2011
    ..Therefore, MAFLD (metabolic syndrome-associated fatty liver disease) might describe both patient populations more accurately and also describes the pathophysiological characteristics...
  37. ncbi request reprint Bridging hyperacute liver failure by ABO-incompatible auxiliary partial orthotopic liver transplantation
    Yara Banz
    Department of Clinical Research, University of Bern, Bern, Switzerland
    Transpl Int 20:722-7. 2007
    ..However, each method is associated with downsides in terms of immunobiology, organ availability and effects on the overall waiting list...
  38. ncbi request reprint Herpes simplex virus hepatitis 4 years after liver transplantation
    Karl Dimiter Bissig
    Division of Internal Medicine, Bern, Inselspital, Switzerland
    J Gastroenterol 38:1005-8. 2003
    ..Therapy with acyclovir was immediately initiated and the patient recovered. This case illustrates the diagnostic importance of mucocutaneous lesions in the assessment of complications after liver transplantation...
  39. ncbi request reprint Expression and regulation of gap junctions in rat cholangiocytes
    Hans Peter Bode
    Department of Gastroenterology, University of Bern, Bern, Switzerland
    Hepatology 36:631-40. 2002
    ..In conclusion, cholangiocytes have the capacity for intercellular communication of second messenger signals via gap junctions in a fashion that is under hormonal control...
  40. pmc Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification
    Diren Beyoglu
    Hepatology Research Group, Department of Clinical Research, University of Bern, Switzerland
    Hepatology 58:229-38. 2013
    ..Conclusion: Tissue metabolomics yielded precise biochemical information regarding HCC tumor metabolic remodeling from mitochondrial oxidation to aerobic glycolysis and the impact of molecular subtypes on this process...
  41. doi request reprint Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease
    Bruno M Strebel
    Department for Visceral Surgery and Medicine, University of Berne, Berne, Switzerland
    Expert Rev Anticancer Ther 8:1743-9. 2008
    ..We also discuss the pros and cons of different schedules of combining such treatments. We conclude that there is enough of a theoretical argument to design clinical trials testing this strategy...
  42. ncbi request reprint Spontaneous regression of an inflammatory pseudotumor of the liver
    E Biecker
    Institut fur Klinische Pharmakologie, Universitat Bern, Schweiz
    Z Gastroenterol 41:991-4. 2003
    ..We report a patient with a histologically proven IPT of the liver that regressed spontaneously over several months without any specific treatment...
  43. doi request reprint Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma
    Anne Christine Piguet
    Institute of Clinical Pharmacology, University of Berne, Berne, Switzerland
    J Hepatol 49:78-87. 2008
    ..Since antiangiogenic therapy may enhance chemotherapy effects, we tested the antitumorigenic properties of sirolimus combined with doxorubicin in experimental HCC...
  44. ncbi request reprint Extended preservation of rat liver graft by induction of heme oxygenase-1
    Claudio A Redaelli
    Department of Visceral and Transplantation Surgery, Institute for Clinical Pharmacology, University of Bern, Bern, Switzerland
    Hepatology 35:1082-92. 2002
    ..The mechanism underlying these beneficial effects does not appear to be prevention of apoptosis...
  45. doi request reprint Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated
    Maria Luisa Balmer
    Institute of Clinical Pharmacology, University of Berne, Berne, Switzerland
    Swiss Med Wkly 138:415-9. 2008
    ..However, statins as well as fibrates seem to have beneficial effects on the primary biliary cirrhosis itself and deserve formal testing within clinical trials...
  46. doi request reprint Hit proteins, mitochondria and cancer
    Juliette Martin
    Institute of Clinical Pharmacology and Visceral Research, University of Bern, Switzerland
    Biochim Biophys Acta 1807:626-32. 2011
    ..The molecular mechanisms by which the HINT and FHIT proteins participate in bioenergetics of cancer are just beginning to be unraveled. Their purported actions as tumor suppressors are highlighted in this review...
  47. ncbi request reprint Rat inositol 1,4,5-trisphosphate receptor isoform 2 interacts with itself in its C-terminal portion and upstream of the first transmembrane domain
    F Magnino
    Department of Clinical Pharmacology, University of Bern, Switzerland
    Eur J Biochem 268:5981-8. 2001
    ..These results advance our understanding of the molecular mechanisms that underlie the oligomerization and interactions of the InsP(3)R subunits during the opening/closing of the Ca(2+) channel...
  48. ncbi request reprint Image of the month. Gamma-Gandy bodies
    Jean Francois Dufour
    Department of Clinical Pharmacology, University of Bern, Switzerland
    Gastroenterology 125:1010, 1294. 2003
  49. ncbi request reprint Congenital dyserythropoietic anaemia type II (HEMPAS) and haemochromatosis: a report of two cases
    Johanna A Kremer Hovinga
    Central Haematology Laboratory, Inselspital, University of Bern, Switzerland
    Eur J Gastroenterol Hepatol 15:1141-7. 2003
    ..Both patients required chelation therapy. This report points out the need to consider CDA in patients presenting with haemochromatosis and anaemia...
  50. ncbi request reprint Hepatocellular antifreeze carrier
    Jean Francois Dufour
    Department of Clinical Pharmacology, University of Berne, Murtenstrasse 35, 3010 Bern, Switzerland
    J Hepatol 39:460-2. 2003
  51. doi request reprint Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
    Andri Rauch
    University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland
    Gastroenterology 138:1338-45, 1345.e1-7. 2010
    ..We performed a genome-wide association study to screen for host genetic determinants of HCV persistence and response to therapy...
  52. doi request reprint Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study
    L Prasad
    Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
    J Viral Hepat 16:644-9. 2009
    ..Our findings emphasize the importance of providing appropriate preventive advice, such as counselling to avoid alcohol intake, in those infected with HCV...
  53. pmc Tumor suppressor and hepatocellular carcinoma
    Juliette Martin
    Department of Clinical Pharmacology, University of Bern, Murtenstrasse, 35, CH 3010 Bern, Switzerland
    World J Gastroenterol 14:1720-33. 2008
    ..The loss of several key tumor suppressors has been described in hepatocellular carcinoma. Here, we systematically review the evidence implicating tumor suppressors in the development of hepatocellular carcinoma...
  54. ncbi request reprint [Transjugular liver core biopsy: indications, results, and complications]
    H P Dinkel
    Institut für Diagnostische Radiologie, Inselspital, Universitat Bern, Switzerland
    Rofo 175:1112-9. 2003
    ..To evaluate benefit, feasibility, and frequency of complications with transjugular liver biopsy using a semi-automatic Tru-cut system...
  55. ncbi request reprint 1 alpha,25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts
    C A Redaelli
    Department of Visceral and Transplantation Surgery, University of Bern, Bern, Switzerland
    Hepatology 34:926-34. 2001
    ..Analogues of vitamin D with fewer hypercalcemic effects may have potential as immunosuppressive drugs in liver transplantation...